Profile data is unavailable for this security.
About the company
EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.
- Revenue in SEK (TTM)264.17m
- Net income in SEK22.71m
- Incorporated2006
- Employees21.00
- LocationEQL Pharma ABStortorget 1LUND 222 23SwedenSWE
- Phone+46 462119170
- Websitehttps://eqlpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Natural Health Trends Corp. | 452.83m | 5.25m | 837.79m | 138.00 | 159.11 | 2.02 | 122.06 | 1.85 | 0.0434 | 0.0434 | 3.75 | 3.42 | 0.582 | 2.24 | -- | 311,695.70 | 0.6751 | -0.5398 | 0.9333 | -0.7099 | 74.30 | 74.06 | 1.16 | -0.9571 | 2.77 | -- | 0.00 | -- | -10.60 | -25.54 | 81.47 | -54.86 | -26.47 | 6.64 |
| 111 Inc - ADR | 21.49bn | -544.70m | 1.06bn | 1.52k | -- | -- | -- | 0.0495 | -0.6106 | -0.6106 | 24.07 | -1.04 | 4.80 | 9.62 | 32.62 | 1,342,754.00 | -10.93 | -17.09 | -- | -178.25 | 5.56 | 5.36 | -2.28 | -4.37 | 0.5234 | -19.99 | 0.4256 | -- | 10.59 | 52.95 | 5.80 | -- | -7.89 | -- |
| Pharmaniaga Berhad | 7.61bn | -173.22m | 1.16bn | 3.78k | -- | -- | -- | 0.1524 | -0.0572 | -0.0572 | 2.55 | -0.2056 | 1.82 | 4.59 | 9.57 | -- | -4.06 | -6.88 | -- | -38.45 | 9.04 | 6.64 | -2.23 | -3.66 | 0.2762 | 1.37 | 1.29 | -- | -3.02 | 7.38 | 87.25 | -- | 23.35 | -- |
| Sopharma Trading AD | 10.11bn | 184.15m | 1.17bn | 2.73k | 6.36 | 1.47 | 3.13 | 0.1158 | 0.9201 | 0.9201 | 50.50 | 3.98 | 2.66 | 0.1586 | 7.16 | 661,702.60 | 4.85 | 2.39 | 14.87 | 7.88 | 97.98 | 98.09 | 1.82 | 1.01 | 0.6231 | 185.95 | 0.6107 | -- | 13.02 | 13.26 | 221.67 | 27.86 | 3.70 | -- |
| Profarma Distribuidora de Produts Frm SA | 17.84bn | 154.76m | 1.31bn | 7.08k | 8.38 | 0.5151 | 2.73 | 0.0734 | 0.6289 | 0.6289 | 72.50 | 10.23 | 1.77 | 4.67 | 7.67 | -- | 1.70 | 1.64 | 4.06 | 3.40 | 14.97 | 14.61 | 0.9618 | 0.9519 | 0.7696 | 1.85 | 0.4552 | -- | 10.82 | 15.19 | -12.95 | -- | 41.08 | -- |
| Charmacy Pharmaceutical Co Ltd | 6.41bn | 74.73m | 1.36bn | 831.00 | 18.23 | 1.57 | 12.03 | 0.2126 | 0.5139 | 0.5139 | 44.07 | 5.98 | 1.44 | 6.05 | 4.88 | 5,728,231.00 | 1.68 | 1.79 | 8.28 | 7.99 | 6.34 | 6.08 | 1.17 | 1.24 | 0.7775 | 2.79 | 0.5111 | 37.09 | 5.47 | 2.27 | -43.25 | 2.48 | -16.01 | 0.0027 |
| EQL Pharma AB | 264.17m | 22.71m | 1.53bn | 21.00 | 68.83 | 8.60 | -- | 5.79 | 0.7642 | 0.7642 | 8.88 | 6.12 | 0.8012 | 1.74 | 4.80 | 12,579,430.00 | 6.89 | 9.02 | 11.90 | 15.27 | 43.55 | 37.95 | 8.59 | 8.29 | 0.5694 | 8.88 | 0.4032 | -- | 1.64 | 39.64 | -26.57 | -- | 32.73 | -- |
| Hemas Holdings PLC | 4.24bn | 213.01m | 1.81bn | 5.83k | 8.50 | 1.20 | 6.46 | 0.4269 | 10.24 | 10.24 | 203.85 | 72.79 | 1.27 | 3.33 | 4.70 | 20,874,320.00 | 6.61 | 5.71 | 12.51 | 10.41 | 29.60 | 29.36 | 5.23 | 4.94 | 1.01 | 5.01 | 0.2236 | 28.30 | 6.74 | 13.67 | 43.10 | 12.64 | -2.33 | 13.12 |
| CM Hospitalar SA | 22.56bn | 654.46m | 1.88bn | 7.00k | 2.80 | 0.2811 | 1.56 | 0.0833 | 1.04 | 1.04 | 36.93 | 10.32 | 1.12 | 5.56 | 4.67 | 1,606,019.00 | 3.25 | 4.00 | 4.51 | 6.15 | 15.13 | 15.89 | 2.90 | 3.50 | 1.68 | 1.56 | 0.576 | -- | 26.72 | 33.22 | 38.57 | 60.22 | -2.72 | -- |
Data as of May 31 2024. Currency figures normalised to EQL Pharma AB's reporting currency: Swedish Krona SEK
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Consensus Asset Management AB (Investment Management)as of 30 Jun 2023 | 700.00k | 0.00% |
| SEB Investment Management ABas of 31 Mar 2023 | 636.49k | 0.00% |
| Carnegie Fonder ABas of 28 Mar 2024 | 440.26k | 0.00% |
| Cliens Kapitalf�rvaltning ABas of 31 Mar 2023 | 308.07k | 0.00% |
| Amundi Asset Management SA (Investment Management)as of 28 Mar 2024 | 51.21k | 0.00% |
More ▼
Data from 30 Jun 2023 - 22 May 2024Source: FactSet Research Systems Inc.
